Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
By N. Kuderer, D. Dale, J. Crawford, G. Lyman. Journal of Clinical Oncology, 2007
707 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/3221cda2567af17a26e927c46079dac917f37036
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “A meta-analysis of prophylactic G-CSF showed a reduction in the incidence of neutropenic fever and early deaths, including infection-related mortality [369].”
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015, methodology): “Meta-analyses of RCTs conducted in varying patient populations have confirmed that primary prophylaxis with a CSF reduces the risk of febrile neutropenia during chemotherapy for a solid tumor or lymphoma.(8,9,12,13,18,19) Primary prophylaxis may also reduce the risk of hospitalization(18) and infect”